Passive immunization with equine RBD-specific Fab protects K18-hACE2-mice against Alpha or Beta variants of SARS-CoV-2

Passive immunization with equine RBD-specific Fab protects K18-hACE2-mice against Alpha or Beta variants of SARS-CoV-2

Emergence of variants of concern (VOC) during the COVID-19 pandemic has contributed to the decreased efficacy of therapeutic monoclonal antibody treatments for severe cases of SARS-CoV-2 infection. In addition, the cost of creating these therapeutic treatments is high, making their implementation in...

Full description

Bibliographic Details
Main Authors: Mariette Barbier, Katherine S. Lee, Mayur S. Vikharankar, Shriram N. Rajpathak, Nandkumar Kadam, Ting Y. Wong, Brynnan P. Russ, Holly A. Cyphert, Olivia A. Miller, Nathaniel A. Rader, Melissa Cooper, Jason Kang, Emel Sen-Kilic, Zeriel Y. Wong, Michael T. Winters, Justin R. Bevere, Ivan Martinez, Rachayya Devarumath, Umesh S. Shaligram, F. Heath Damron
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Immunology
Subjects:
SARS-CoV-2
COVID-19
Equine F(ab’)2
EpF(ab’)2
passive immunization
polyclonal antibodies
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.948431/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.948431/full

Similar Items